Oxcarbazepine Tablet, Film Coated
Product Images NDC 90096-171

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 90096-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zameer Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Oxcarbazepine 1)

Label for Oxcarbazepine Tablets, USP 150 mg film-coated tablets by Zameer Pharmaceuticals LLC. The label includes the NDC 90096-171-01 and indicates a package count of 100 tablets. It specifies storage conditions and notes the manufacturer as Umedica Laboratories Pvt. Ltd. in India, with distribution by Zameer Pharmaceuticals in Iselin, NJ.*

FDA Label Image

Image Description (Oxcarbazepine 2)

Label for Oxcarbazepine Tablets, USP 300 mg oral film-coated tablets. The carton indicates a quantity of 100 tablets, manufactured by Umedica Laboratories Pvt. Ltd., India, and distributed by Zameer Pharmaceuticals LLC in Iselin, NJ. Storage instructions and other regulatory details are included.*

FDA Label Image

Image Description (Oxcarbazepine 3)

Oxcarbazepine Tablets USP 600 mg film-coated oral tablets label with 100 tablets per container. Manufactured by Umedica Laboratories Pvt. Ltd., India, and distributed by Zameer Pharmaceuticals LLC, Iselin, NJ. The label includes storage instructions, dosage direction to see package insert, and barcode with GTIN, serial number, expiration date, and lot number placeholders.*

FDA Label Image

"image Description" (Oxcarbazepine Tabs Usp Graph 1)

A Kaplan-Meier plot showing exit rates over time on trial from Day 2 to Day 11 comparing two treatment groups: Oxcarbazepine and Placebo. The x-axis represents time in days, and the y-axis represents the exit rate. The graph indicates a statistically significant difference between groups with a log-rank test p-value of 0.0001.*

FDA Label Image

"image Description" (Oxcarbazepine Tabs Usp Graph 2)

A line graph depicting seizure rate over days from first dose to first seizure for two treatment groups: Oxcarbazepine and Placebo. The x-axis represents days from first dose to first seizure (0 to 140 days), and the y-axis shows seizure rate (0.0 to 1.0). The graph includes a log-rank test p-value of 0.046 comparing the groups.*

FDA Label Image

"image Description" (Oxcarbazepine Tabs Usp Graph 3)

A line chart depicting exit rates over time in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days, ranging from 0 to 130, while the y-axis shows exit rates from 0.0 to 1.0. The LOW group shows a steeper increase than the HIGH group, with a log-rank test p-value of 0.0001 displayed on the graph.*

FDA Label Image

"image Description" (Oxcarbazepine Tabs Usp Graph 4)

A Kaplan-Meier survival curve graph displaying exit rates over time (days) for two treatment groups labeled 'HIGH' and 'LOW.' The y-axis represents the exit rate from 0 to 1, and the x-axis represents time to exit in days from 0 to 130. The 'LOW' group shows a higher and faster exit rate than the 'HIGH' group. A log-rank test p-value of 0.0001 is indicated on the graph.*

FDA Label Image

"image Description" (Oxcarbazepine Tabs Usp Structure)

Chemical structure diagram of oxcarbazepine, showing the molecular arrangement including two benzene rings, a lactam ring, and an amide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.